55.77 USD
-0.52 (-0.92%)
Overall BMRN gets a fundamental rating of 6 out of 10. We evaluated BMRN against 533 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
BMRN had positive earnings in the past year.
In the past year BMRN had a positive cash flow from operations.
BMRN had positive earnings in 4 of the past 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BMRN (6.83%) is better than 92.68% of its industry peers.
BMRN's Return On Equity of 8.59% is amongst the best of the industry. BMRN outperforms 92.87% of its industry peers.
With an excellent Return On Invested Capital value of 7.69%, BMRN belongs to the best of the industry, outperforming 93.81% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.83%.
The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN's Profit Margin of 16.82% is amongst the best of the industry. BMRN outperforms 93.43% of its industry peers.
BMRN's Operating Margin of 20.21% is amongst the best of the industry. BMRN outperforms 94.56% of its industry peers.
BMRN's Gross Margin of 81.32% is amongst the best of the industry. BMRN outperforms 84.99% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BMRN has more shares outstanding
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
BMRN has an Altman-Z score of 5.36. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 5.36, BMRN is doing good in the industry, outperforming 74.86% of the companies in the same industry.
BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
The Debt to FCF ratio of BMRN (0.72) is better than 94.18% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.10, BMRN is doing worse than 62.85% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.36 |
ROIC/WACC0.93
WACC8.25%
2.3 Liquidity
A Current Ratio of 4.83 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Current ratio (4.83) which is in line with its industry peers.
A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
With a Quick ratio value of 3.10, BMRN is not doing good in the industry: 60.04% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.00% over the past year.
BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 27.59% on average per year.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.34% yearly.
EPS Next Y37.42%
EPS Next 2Y42.81%
EPS Next 3Y33.39%
EPS Next 5Y27.59%
Revenue Next Year12.45%
Revenue Next 2Y9.95%
Revenue Next 3Y9.2%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.97, which indicates a rather expensive current valuation of BMRN.
Based on the Price/Earnings ratio, BMRN is valued cheaper than 93.62% of the companies in the same industry.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (25.98), we can say BMRN is valued inline with the index average.
With a Price/Forward Earnings ratio of 12.37, BMRN is valued correctly.
97.19% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
BMRN is valuated cheaply when we compare the Price/Forward Earnings ratio to 35.79, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.97 | ||
| Fwd PE | 12.37 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 95.31% of the companies are valued more expensively.
BMRN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.97 | ||
| EV/EBITDA | 13.7 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.39% in the coming years.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y42.81%
EPS Next 3Y33.39%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BMRN (11/26/2025, 2:36:03 PM)
55.77
-0.52 (-0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change-1%
Ins Owners0.65%
Ins Owner Change0.18%
Market Cap10.71B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts83.53
Price Target94.11 (68.75%)
Short Float %5.18%
Short Ratio4.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-3.35%
PT rev (3m)-4.75%
EPS NQ rev (1m)10.87%
EPS NQ rev (3m)13.35%
EPS NY rev (1m)-10.53%
EPS NY rev (3m)-12.96%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.97 | ||
| Fwd PE | 12.37 | ||
| P/S | 3.46 | ||
| P/FCF | 12.97 | ||
| P/OCF | 11.72 | ||
| P/B | 1.77 | ||
| P/tB | 1.9 | ||
| EV/EBITDA | 13.7 |
EPS(TTM)2.66
EY4.77%
EPS(NY)4.51
Fwd EY8.08%
FCF(TTM)4.3
FCFY7.71%
OCF(TTM)4.76
OCFY8.54%
SpS16.11
BVpS31.54
TBVpS29.31
PEG (NY)0.56
PEG (5Y)N/A
Graham Number43.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.36 |
F-Score8
WACC8.25%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y37.42%
EPS Next 2Y42.81%
EPS Next 3Y33.39%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.45%
Revenue Next 2Y9.95%
Revenue Next 3Y9.2%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.49%
EBIT Next 3Y41.32%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
Can you provide the valuation status for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 37.42% in the next year.